Pulmonx (LUNG) Competitors

Pulmonx (NASDAQ:LUNG) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Is LUNG or BLFS more profitable?

BioLife Solutions has a net margin of -38.98% compared to Pulmonx's net margin of -67.31%. BioLife Solutions' return on equity of -6.61% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-67.31%	-55.36%	-33.53%
BioLife Solutions	-38.98%	-6.61%	-5.54%

Does the MarketBeat Community prefer LUNG or BLFS?

BioLife Solutions received 276 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 67.39% of users gave BioLife Solutions an outperform vote while only 45.57% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 36 45.57%	Underperform Votes 43 54.43%
BioLife Solutions	Outperform Votes 312 67.39%	Underperform Votes 151 32.61%

Which has more volatility & risk, LUNG or BLFS?

Pulmonx has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in LUNG or BLFS?

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, LUNG or BLFS?

Pulmonx has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79M	3.27	-$60.84M	-$1.44	-4.78
BioLife Solutions	$82.25M	14.75	-$66.43M	-$0.50	-51.64

Do analysts prefer LUNG or BLFS?

Pulmonx currently has a consensus price target of $13.36, suggesting a potential upside of 94.14%. BioLife Solutions has a consensus price target of $29.86, suggesting a potential upside of 15.64%. Given Pulmonx's higher probable upside, equities analysts clearly believe Pulmonx is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
BioLife Solutions	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to LUNG or BLFS?

In the previous week, BioLife Solutions had 6 more articles in the media than Pulmonx. MarketBeat recorded 11 mentions for BioLife Solutions and 5 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.84 beat BioLife Solutions' score of 0.81 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLife Solutions beats Pulmonx on 11 of the 17 factors compared between the two stocks.